HIV and cardiovascular risk

Clinical Medicine, Journal of the Royal College of Physicians of London

Volumn 8, Issue 3, 2008, Pages 315-318

  Moyle, Graeme ^a   Randell, Paul ^a,b  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b St Stephen's Centre   (United Kingdom)

Author keywords

Antiretroviral therapy HAART; Cardiovasuclar risk; HIV; Hypercholesterolemia; Metabolic side effects

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; INDINAVIR; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; ZIDOVUDINE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MORBIDITY; MORTALITY; PREVALENCE; REVIEW; UNITED KINGDOM;

EID: 46949093359     PISSN: 14702118     EISSN: None     Source Type: Journal    
DOI: 10.7861/clinmedicine.8-3-315     Document Type: Review

References (18)

1. The UK Collaborative Group for HIV and STI Surveillance. A complex picture. HIV and other sexually transmitted infections in the United Kingdom: 2006. London: Health Protection Agency, Centre for Infections, 2006. www.hpa.org.uk/publications/2006/ hiv_sti_2006/pdf/a_complex_Picture_2006 _last. pdf
2. Riddler SA, Smit E, Cole SR et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978-82.
3. Friis-Møller N, Sabin CA, Weber R et al. Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003;349:1993-2003.
4. DAD Study Group, Friis-Møller N, Reiss P et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.
5. Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren JD et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96.
6. Kuller L, SMART Study group. Elevated levels of Interleukin-6 and D-dimers are associated with an increased risk of death in patients with HIV. 15th Conference on Retroviruses and Opportunistic Infections Boston, February 3-6, 2008. Abstract 139.
7. Grinspoon S, Carr A, Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005;352:48-62.
8. Fontas E, van Leth F, Sabin CA et al. D:A:D Study Group. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? J Infect Dis 2004; 189:1056-74.
9. Fleischman A, Johnsen S, Systrom D et al. Effects of a nucleoside reverse transcriptase inhibitor, stavudine, on glucose disposal and mitochondrial function in muscle of healthy adults. Am J Physiol Endocrinol Metab 2007;292:E1666-73.
10. Noor MA, Flint OP, Maa JF, Parker RA. Effects of Atazanavir/ritonavir and Lopinavir/ritonavir on Glucose Uptake and Insulin Sensitivity: Demonstrable Differences in Vitro and Clinically. AIDS 2006;20:1813-21.
11. Sterne JA, May M, Bucher HC et al. HAART and the heart: changes in coronary risk factors and implications for coronary risk in men starting antiretroviral therapy. J Intern Med 2007;261:255-67.
12. Law MG, Friis-Moller N, El-Sadr et al. The use of the Framingham Equation to predict Myocardial Infarctions in HIV-infected patients: Comparison with observed events in the D:A:D study. HIV Med 2006;7;218.
13. Friis-Møller N, Thiébaut R, Reiss P et al. Predicting the risk of coronary heart disease in HIV-infected patients: the D:A:D risk equation. CROI 2007.Poster 808.
14. Geraix J, Souza ME, Delatim FC, Pereira PC. Bezafibrate for the treatment of hypertriglyceridemia in HIV1-infected patients on highly active antiretroviral therapy. Braz J Infect Dis 2006;10:159-64.
15. Geletko SM, ZuWallack AR. Treatment of hyperlipidemia in HIV-infected patients. Am J Health SystPharm 58;7:607-14.
16. Fichtenbaum CJ, Gerber JG, Rosenkranz SL et al. NIAID AIDS Clinical Trials Group. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS 2002;16:569-77.
17. Colafigli M, Di Giambenedetto S, Bracciale L et al. Cardiovascular risk score change in HIV-1-infected patients switched to an atazanavir-based combination anti-retroviral regimen HIV Medicine 2008;9: 172-9.
18. Soriano V, García-Gasco P, Vispo E et al. Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial. J Antimicrob Chemother 2008;61:200-5.